{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:17:35Z","timestamp":1778696255021,"version":"3.51.4"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:p>Objective. To determine the optimal treatment for childhood Guillain-Barre\u0301 syndrome (GBS).<\/jats:p>\n               <jats:p>Methods. We performed a randomized, multicenter study of GBS according to international diagnostic criteria. In study 1 (early treatment), children able to walk unaided for 5 meters were randomized for 1 g\/kg intravenously administered immunoglobulin (IVIG) over 2 days or no treatment. The primary outcome measure was the degree of disability at nadir. In study 2 (treatment for severe GBS), children unable to walk 5 meters unaided were randomized for 1 g\/kg IVIG over 2 days or 0.4 g\/kg IVIG over 5 days. The primary outcome measure was the number of days needed to regain the ability to walk unaided. Children randomized for no treatment in study 1 could enter study 2 if loss of unaided walking occurred.<\/jats:p>\n               <jats:p>Results. Ninety-five children with GBS were registered in 40 months. Twenty-one children were randomized in study 1 and 51 in study 2 (5 after deterioration in study 1). Twenty-eight children were not randomized for various reasons. Eleven of 21 patients in study 1 lost the ability to walk unassisted and 6 were bedridden, with no statistically significant difference between the children initially randomized for treatment versus no treatment. Recovery occurred faster in the group randomized for early treatment. In study 2, recovery did not differ significantly between the children treated for 2 days versus 5 days (median time to unaided walking: 19 days vs 13 days). Secondary transient deterioration in the disability score occurred more frequently in the group with the 2-day regimen than in the group treated for 5 days (5 of 23 patients vs 0 of 23 patients). Multivariate analysis with Cox regression showed that disease severity at the nadir was the only prognostic factor for recovery.<\/jats:p>\n               <jats:p>Conclusions. Treatment with IVIG before loss of unaided walking did not give rise to a less severe course, but recovery occurred somewhat faster. However, given the small number of patients, the power of this conclusion is low. For treatment after loss of unaided walking, there was no significant difference in the effectiveness of 2 g\/kg IVIG administered over 2 days versus 5 days. Early \u201crelapses\u201d occurred more frequently after the shorter treatment regimen.<\/jats:p>","DOI":"10.1542\/peds.2004-1324","type":"journal-article","created":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T18:17:49Z","timestamp":1120241869000},"page":"8-14","source":"Crossref","is-referenced-by-count":152,"title":["Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre\u0301 Syndrome: A Randomized Trial"],"prefix":"10.1542","volume":"116","author":[{"given":"Rudolf","family":"Korinthenberg","sequence":"first","affiliation":[{"name":"Division of Neuropediatrics and Muscular Disorders, Department of Pediatrics and Adolescent Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Schessl","sequence":"additional","affiliation":[{"name":"Division of Neuropediatrics and Muscular Disorders, Department of Pediatrics and Adolescent Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Division of Neuropediatrics and Muscular Disorders, Department of Pediatrics and Adolescent Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju\u0308rgen Schulte","family":"Mo\u0308nting","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Informatics, University Hospital Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"2021120905524978400_R1","doi-asserted-by":"crossref","unstructured":"Asbury A. New concepts of Guillain-Barre\u0301 syndrome. J Child Neurol.\u20082000;15:183\u2013191","DOI":"10.1177\/088307380001500308"},{"key":"2021120905524978400_R2","doi-asserted-by":"crossref","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre\u0301 syndrome. Ann Neurol.\u20081990;27:S21\u2013S24","DOI":"10.1002\/ana.410270707"},{"key":"2021120905524978400_R3","doi-asserted-by":"crossref","unstructured":"Royden-Jones H. Childhood Guillain-Barre\u0301 syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol.\u20081996;11:4\u201312","DOI":"10.1177\/088307389601100102"},{"key":"2021120905524978400_R4","doi-asserted-by":"crossref","unstructured":"van Koningsveld R, van Doorn PA, Schmitz PIM, et al. Mild forms of Guillain-Barre\u0301 syndrome in an epidemiologic survey in the Netherlands. Neurology.\u20082000;54:620\u2013625","DOI":"10.1212\/WNL.54.3.620"},{"key":"2021120905524978400_R5","doi-asserted-by":"crossref","unstructured":"Guillain-Barre\u0301 Syndrome Study Group. Plasmapheresis and acute Guillain-Barre\u0301 syndrome. Neurology.\u20081985;35:1096\u20131104","DOI":"10.1212\/WNL.35.8.1096"},{"key":"2021120905524978400_R6","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Plasma Exchange and Guillain-Barre\u0301 Syndrome. Efficiency of plasma exchange in Guillain-Barre\u0301 syndrome: role of replacement fluids. Ann Neurol.\u20081987;22:753\u2013761","DOI":"10.1002\/ana.410220612"},{"key":"2021120905524978400_R7","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barre\u0301 syndrome. Cochrane Database Syst Rev.\u20082002;(2):CD001798","DOI":"10.1002\/14651858.CD001798"},{"key":"2021120905524978400_R8","doi-asserted-by":"crossref","unstructured":"Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre\u0301 syndrome. Neurology.\u20081996;46:100\u2013103","DOI":"10.1212\/WNL.46.1.100"},{"key":"2021120905524978400_R9","doi-asserted-by":"crossref","unstructured":"Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre\u0301 syndrome. Cochrane Database Syst Rev.\u20082004;(1):CD002063","DOI":"10.1002\/14651858.CD002063.pub2"},{"key":"2021120905524978400_R10","doi-asserted-by":"crossref","unstructured":"Plasma Exchange\/Sandoglobulin Gullain-Barre\u0301 Syndrome Trial Group. A randomized trial comparing intravenous immune globulins and plasma exchange in Guillain-Barre\u0301 syndrome. Lancet.\u20081997;349:225\u2013230","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"2021120905524978400_R11","doi-asserted-by":"crossref","unstructured":"van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre\u0301 syndrome: Dutch Guillain-Barre\u0301 Study Group. N Engl J Med.\u20081992;326:1123\u20131129","DOI":"10.1056\/NEJM199204233261705"},{"key":"2021120905524978400_R12","doi-asserted-by":"crossref","unstructured":"Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barre\u0301 syndrome. Ann Neurol.\u20081990;28:65\u201369","DOI":"10.1002\/ana.410280112"},{"key":"2021120905524978400_R13","doi-asserted-by":"crossref","unstructured":"Kathri BO, Flamini R, Baruah JK, et al. Plasmapheresis with acute inflammatory polyneuropathy. Pediatr Neurol.\u20081990;6:17\u201319","DOI":"10.1016\/0887-8994(90)90073-A"},{"key":"2021120905524978400_R14","doi-asserted-by":"crossref","unstructured":"Jansen PW, Perkin RM, Ashwal S. Guillain-Barre\u0301 syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol.\u20081993;9:16\u201320","DOI":"10.1016\/0887-8994(93)90004-V"},{"key":"2021120905524978400_R15","doi-asserted-by":"crossref","unstructured":"Vajsar J, Sloane A, Wood E, Murphy EG. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barre\u0301 syndrome. Arch Pediatr Adolesc Med.\u20081994;148:1210\u20131212","DOI":"10.1001\/archpedi.1994.02170110096019"},{"key":"2021120905524978400_R16","doi-asserted-by":"crossref","unstructured":"Korinthenberg R, Schulte Mo\u0308nting J. Natural history and treatment effects in Guillain-Barre\u0301 syndrome: a multicentre study. Arch Dis Child.\u20081996;74:281\u2013287","DOI":"10.1136\/adc.74.4.281"},{"key":"2021120905524978400_R17","doi-asserted-by":"crossref","unstructured":"Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain-Barre\u0301 syndrome. J Child Neurol.\u20081997;12:376\u2013380","DOI":"10.1177\/088307389701200607"},{"key":"2021120905524978400_R18","doi-asserted-by":"crossref","unstructured":"McGhee B, Jarjour IT. Single-dose intravenous immune globulin for treatment of Guillain-Barre\u0301 syndrome. Am J Hosp Pharm.\u20081994;51:97\u201399","DOI":"10.1093\/ajhp\/51.1.97"},{"key":"2021120905524978400_R19","doi-asserted-by":"crossref","unstructured":"Gu\u0308rses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barre\u0301 syndrome. Scand J Infect Dis.\u20081995;27:241\u2013243","DOI":"10.3109\/00365549509019016"},{"key":"2021120905524978400_R20","doi-asserted-by":"crossref","unstructured":"Shahar E, Shorer Z, Roifman CM, et al. Immune globulins are effective in severe pediatric Guillain-Barre\u0301 syndrome. Pediatr Neurol.\u20081997;16:32\u201336","DOI":"10.1016\/S0887-8994(96)00253-6"},{"key":"2021120905524978400_R21","doi-asserted-by":"crossref","unstructured":"Kanra G, Ozon A, Vajsar J, et al. Intravenous immunoglobulin treatment in children with Guillain-Barre\u0301 syndrome. Eur J Paediatr Neurol.\u20081997;1:7\u201312","DOI":"10.1016\/S1090-3798(97)80004-9"},{"key":"2021120905524978400_R22","doi-asserted-by":"crossref","unstructured":"Haupt WF, Rosenow F, van der Ven C, et al. Sequential treatment of Guillain-Barre\u0301 syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci.\u20081996;137:145\u2013149","DOI":"10.1016\/0022-510X(95)00357-8"},{"key":"2021120905524978400_R23","doi-asserted-by":"crossref","unstructured":"Delanoe C, Sebire G, Landrieu P, et al. Acute inflammatory demyelinating polyradiculoneuropathy in children: clinical and electrodiagnostic studies. Ann Neurol.\u20081998;44:350\u2013356","DOI":"10.1002\/ana.410440310"},{"key":"2021120905524978400_R24","doi-asserted-by":"crossref","unstructured":"Green D, Ropper AH. Mild Guillain-Barre\u0301 syndrome. Arch Neurol.\u20082001;58:1098\u20131101","DOI":"10.1001\/archneur.58.7.1098"},{"key":"2021120905524978400_R25","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Plasma Exchange in Guillain-Barre\u0301 Syndrome. Appropriate number of plasma exchanges in Guillain-Barre\u0301 syndrome. Ann Neurol.\u20081997;41:298\u2013306","DOI":"10.1002\/ana.410410304"},{"key":"2021120905524978400_R26","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barre\u0301 syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry.\u20082001;71:235\u2013238","DOI":"10.1136\/jnnp.71.2.235"},{"key":"2021120905524978400_R27","doi-asserted-by":"crossref","unstructured":"Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barre\u0301 syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry.\u20081991;54:957\u2013960","DOI":"10.1136\/jnnp.54.11.957"},{"key":"2021120905524978400_R28","doi-asserted-by":"crossref","unstructured":"Irani DN, Cornblath DR, Chaudhry V, et al. Relapse in Guillain-Barre\u0301 syndrome after treatment with human immune globulin. Neurology.\u20081993;43:872\u2013875","DOI":"10.1212\/WNL.43.5.872"},{"key":"2021120905524978400_R29","doi-asserted-by":"crossref","unstructured":"Romano JG, Rotta FT, Potter P, et al. Relapses in the Guillain-Barre\u0301 syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve.\u20081998;21:1327\u20131330","DOI":"10.1002\/(SICI)1097-4598(199810)21:10<1327::AID-MUS14>3.0.CO;2-Z"},{"key":"2021120905524978400_R30","doi-asserted-by":"crossref","unstructured":"Mc Khann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barre\u0301 syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol.\u20081988;23:347\u2013353","DOI":"10.1002\/ana.410230406"},{"key":"2021120905524978400_R31","doi-asserted-by":"crossref","unstructured":"Reisin RC, Pociecha J, Rodriguez E, et al. Severe Guillain-Barre\u0301 syndrome in childhood treated with human immune globulin. Pediatr Neurol.\u20081996;14:308\u2013312","DOI":"10.1016\/0887-8994(96)00050-1"},{"key":"2021120905524978400_R32","doi-asserted-by":"crossref","unstructured":"Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barre\u0301 syndrome: a reappraisal. Ann Neurol.\u20081999;46:701\u2013707","DOI":"10.1002\/1531-8249(199911)46:5<701::AID-ANA4>3.0.CO;2-7"},{"key":"2021120905524978400_R33","doi-asserted-by":"crossref","unstructured":"Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barre\u0301 syndrome. N Engl J Med.\u20081995;333:1374\u20131379","DOI":"10.1056\/NEJM199511233332102"},{"key":"2021120905524978400_R34","doi-asserted-by":"crossref","unstructured":"Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre\u0301 syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol.\u20082000;48:624\u2013631","DOI":"10.1002\/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O"},{"key":"2021120905524978400_R35","doi-asserted-by":"crossref","unstructured":"Watson JDG, Gibson J, Joshua DE, Kronenberg H. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry.\u20081991;54:275\u2013276","DOI":"10.1136\/jnnp.54.3.275"},{"key":"2021120905524978400_R36","doi-asserted-by":"crossref","unstructured":"Oomes PG, van der Meche FG, Kleyweg RP. Liver function disturbances in Guillain-Barre\u0301 syndrome: a prospective longitudinal study in 100 patients: Dutch Guillain-Barre\u0301 Study Group. Neurology.\u20081996;46:96\u2013100","DOI":"10.1212\/WNL.46.1.96"},{"key":"2021120905524978400_R37","doi-asserted-by":"crossref","unstructured":"Warrier I, Bussel JB, Valdez L, et al. Safety and efficacy of low-dose intravenous immune globuline (IVIG) treatment for infants and children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol.\u20081997;19:197\u2013201","DOI":"10.1097\/00043426-199705000-00004"},{"key":"2021120905524978400_R38","doi-asserted-by":"crossref","unstructured":"Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders: a prospective study. J Neurol.\u20082003;250:818\u2013821","DOI":"10.1007\/s00415-003-1085-1"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/1\/8\/1033657\/zpe00705000008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/1\/8\/1033657\/zpe00705000008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:48:32Z","timestamp":1639093712000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/1\/8\/72915\/Intravenously-Administered-Immunoglobulin-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,7,1]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-1324","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}